Co-existence of COPD and left ventricular dysfunction in vascular surgery patients  by Flu, Willem-Jan et al.
Respiratory Medicine (2010) 104, 690e696ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedCo-existence of COPD and left ventricular
dysfunction in vascular surgery patients*Willem-Jan Flu a, Yvette R.B.M. van Gestel b, Jan-Peter van Kuijk a,
Sanne E. Hoeks b, Ruud Kuiper a, Hence J.M. Verhagen c,
Jeroen J. Bax b, Don D. Sin d, Don Poldermans c,*a Department of Anaesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands
b Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
c Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
d Department of Medicine, University of British Columbia and The James Hogg iCAPTURE Center,
St. Paul’s Hospital, Vancouver, Canada
Received 2 July 2009; accepted 21 November 2009
Available online 14 December 2009KEYWORDS
COPD;
Left ventricular
dysfunction;
Vascular surgery* Institution at which the work was
* Corresponding author. Department
The Netherlands. Tel.: þ31 10 703461
E-mail address: d.poldermans@era
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.11.013Summary
Background: The co-existence between chronic obstructive pulmonary disease (COPD) and
heart failure has been previously described. However, the co-existence between COPD and
subclinical left ventricular (LV) dysfunction, without the presence of heart failure symptoms,
is less well understood. This study determined the relationship and clinical relevance of COPD
and subclinical LV dysfunction in vascular surgery patients.
Methods: 1005 consecutive vascular surgery patients were included in which COPD was deter-
mined using spirometry and LV function using echocardiography. Mild COPD was defined as
FEV1 80% of predicted þ FEV1/FVC-ratio< 0.70. Moderate/severe COPD was defined as
FEV1< 80% of predictedþ FEV1/FVC-ratio< 0.70. Systolic LV dysfunction was defined as LV
ejection fraction <50% and diastolic LV dysfunction was diagnosed based on E/A-ratio, pulmo-
nary vein flow and deceleration time. Multivariate regression analyses were used to evaluate
the impact of COPD and LV dysfunction on all-cause mortality. The mean follow-up time was
2.2 1.8 years.
Results: Both, mild and moderate/severe COPD were associated with increased risk for
subclinical LV dysfunction with odds ratio of 1.6 (95%-CIZ 1.1e2.3) and 1.7 (95%-
CIZ 1.2e2.4), respectively. Mild- or moderate/severe COPD in combination with LV
dysfunction was associated with increased risk for all-cause mortality (mild: hazard ratio
1.7; 95%-CIZ 1.1e3.6, moderate/severe: hazard ratio 2.5; 95%-CIZ 1.5e4.7).performed: The Erasmus Medical Center, Rotterdam, The Netherlands.
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Co-existence of COPD and left ventricular dysfunction 691Conclusions: COPD was associated with increased risk for subclinical LV dysfunction.
COPDþ subclinical LV dysfunction was associated with increased risk for all-cause mortality
compared to patients with COPDþ normal LV function. Echocardiography may be useful to
detect subclinical cardiovascular disease and risk-stratify COPD patients undergoing vascular
surgery.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Every year, there are 100 million adults who undergo a non-
cardiac surgical procedure across the world.1 This number
is expected to increase by 25% by 2020.2 The risk of peri-
operative complications increases in patients with co-
morbidities. There is increasing evidence that chronic lung
disease, such as chronic obstructive pulmonary disease
(COPD), and cardiovascular disease are common co-
morbidities in these surgical patients. Interestingly, it
appears that these co-morbidities are inter-related and
often co-exist in the same patients, independent of age and
smoking history.3,4 These patients have extremely poor
prognosis following surgery. With the increasing preopera-
tive use of echocardiography and spirometry, it may now be
possible to identify patients with mild COPD and subclinical
left ventricular (LV) dysfunction prior to surgery, providing
an opportunity to determine the clinical significance of
mild COPD and subclinical LV dysfunction in patients
undergoing non-cardiac surgical procedures. In the current
study, we determined the relationship of LV dysfunction to
COPD and the impact that these co-morbidities have,
independently and collectively, on the risk of mortality in
these patients. We hypothesized that COPD would be
independently associated with LV dysfunction and that the
presence of even subclinical LV dysfunction in patients with
COPD would significantly increase the risk of mortality.
Material and methods
Study population
The patient population consisted of 1005 consecutive
patients undergoing surgery to repair lower extremity
artery, abdominal aortic aneurysm, abdominal aortic
stenosis or carotid artery. Both open and endovascular
procedures were included. The study was performed at the
department of vascular surgery of the Erasmus Medical
Center in Rotterdam, the Netherlands, during the time
period of 2002e2008. The study was approved by the hos-
pital’s ethics committee and performed with informed
consent of all patients.
Baseline characteristics
Prior to surgery, a detailed history was obtained from every
patient. Cardiac history was assessed and ischemic heart
disease was defined as a history of angina pectoris, coronary
revascularization or myocardial infarction. Additional clin-
ical data included age, gender, cerebrovascular disease
(defined as a history of ischemic or hemorrhagic stroke),abdominal aortic disease (defined as abdominal aortic
aneurysm or stenosis), renal dysfunction (serum crea-
tinine> 2.0 mg/dL), diabetesmellitus (fasting blood glucose
7.0 mmol/l or requirement for insulin and/or oral anti-
diabeticmedication), hypertension (definedas systolic blood
pressure 140mmHg, diastolic blood pressure 90mmHg in
non-diabetics, systolic blood pressure 130mmHg, diastolic
blood pressure 80mmHg in diabetics or the use of antihy-
pertensive medication), hypercholesterolemia (defined as
LDL cholesterol> 3.5 mmol/l and/or the requirement of
lipid-lowering medication) and smoking status. The use of
the prescription medications was captured and included
beta-blockers, statins, aspirin, oral anticoagulants, angio-
tensin-converting enzyme (ACE) inhibitors, diuretics,
nitrates, corticosteroids and bronchodilators.
Chronic obstructive pulmonary disease
The diagnosis of COPD was based on preoperative post-
bronchodilator spirometry, which was performed in 95% of
the patients according to the guidelines of the Global
Initiative for Chronic Obstructive Lung Disease (GOLD). Mild
COPD was defined as forced expiratory volume in one
second (FEV1) 80% of predicted or greater in the presence
of FEV1/forced vital capacity (FVC) ratio of <0.70.
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Moderate/severe COPD was defined as FEV1/FVC< 0.70 and
FEV1< 80% of the predicted. In those patients who did not
have spirometry, the diagnosis of COPD was based on
symptoms (dyspnea, sputum production, and/or cough)
plus the use of a pulmonary medication such as broncho-
dilators and corticosteroids.
Left ventricular function
Preoperatively, transthoracic echocardiography was per-
formed in all patients using a handheld Acuson Cypress
Ultrasound System (7V3c transducer). Standard parasternal
and apical 2- and 4-chamber views were obtained during
rest with the patient in the left lateral decubitus position as
recommended.6 Left ventricular end-systolic and end-
diastolic volumes were determined and LV ejection fraction
was calculated using the biplane Simpson’s technique.7
Systolic (S) and diastolic (D) pulmonary vein flow, deceler-
ation time and mitral inflow E/A ratios of peak velocities (at
early rapid filling E and late filling due to atrial contraction
A) were determined in apical 4-chamber view as recom-
mended by the American Society of Echocardiography.8
Systolic LV dysfunction was defined as LV ejection fraction
<50%.9 Diastolic LV dysfunction was confirmed in patients
with E/A-ratio <0.8 (impaired relaxation) or >2 (restrictive
relaxation).10 Abnormal pulmonary vein flow (S/D< 1) was
used to distinguish normal and pseudo-normal diastolic LV
692 W.-J. Flu et al.function in patients with E/A-ratio between 0.8 and 2.11
Deceleration time> 220 ms (impaired relaxation) or
<140 ms (restrictive relaxation) defined diastolic LV
dysfunction in patients with atrial fibrillation.11 Patients
with both systolic and diastolic LV dysfunction were clas-
sified as systolic LV dysfunction. The presence of LV
dysfunction in combination with heart failure symptoms
(shortness of breath, fatigue, exercise intolerance, signs of
fluid retention9) defined symptomatic heart failure,
confirmed in patients with New York Heart Association
functional class I.
Follow-up and outcome
Survival status was determined using municipal civil regis-
tries. The mean follow-up time was 2.2 1.8 years.
Statistical analysis
Dichotomous data are described as numbers and percent-
ages. Continuous variables are described as mean-
s standard deviation. Continuous data were compared
using ANOVA and categorical data were compared using
a Chi Square test. Cumulative long-term survival was
determined using the KaplaneMeier method. Univariate
and multivariate Cox regression analyses were performed
to evaluate the relationship of COPD and LV dysfunction
with all-cause mortality. Multivariate regression analyses
were adjusted for age, gender, ischemic heart disease,
cerebrovascular disease, renal dysfunction, diabetes mel-
litus, hypertension, hypercholesterolemia and smoking
status. A sub-analysis was performed to evaluate the
prognostic value of COPD towards postoperative outcome,
in addition to the Revised Cardiac Risk (RCR) Index.12
Multivariate regression analyses were adjusted for RCR risk
factors (high-risk type of surgery, symptomatic heart
failure, ischemic heart disease, cerebrovascular disease,
renal dysfunction and diabetes) next to age, gender
hypertension, hypercholesterolemia and smoking status.
We report both the crude and the adjusted hazard ratiosFigure 1 Prevalence of chronic obstructive pulmonary disease
COPDZ chronic obstructive pulmonary disease, LVZ left ventricu(HR) with their 95% confidence interval (95%-CIs). For all
tests, a p-value <0.05 (2 sided) was considered significant.
All analyses were performed using SPSS version 15.0
statistical software (SPSS, Inc., Chicago, Illinois).
Results
The baseline study population consisted of 1005 patients
undergoing lower extremity artery (nZ 356), abdominal
aortic aneurysm or abdominal aortic stenosis (nZ 411) or
carotid artery repair (nZ 238). Endovascular procedures
comprised 36% of the surgical procedures. A majority of the
patients were men (77%) and the mean age was 67 (stan-
dard deviationZ 10) years.
Prevalence of COPD and LV dysfunction
In total, 638 (64%) patients had no COPD and of the 367
(37%) with COPD: 175 (17%%) had mild and 192 (19%) had
moderate/severe COPD. At baseline, LV dysfunction was
present in 506 (50%) patients. Of the 103 patients with
symptomatic heart failure, 69 (67%) patients had LVEF 40
and 34 (33%) patients had a LVEF >40%þ abnormal diastolic
parameters. Of the 403 patients with subclinical LV
dysfunction, 130 (32%) patients had LVEF 40%, 64 (16%)
patients had LVEF >40e50% and 209 (52%) patients had
LVEF >50%þ abnormal diastolic parameters (177 patients
with abnormal E/A-ratio and 32 patients with S/D< 1 or
abnormal deceleration time).
Of the patients with no COPD, 232/638 (36%) had
subclinical LV dysfunction and 52/638 (8%) had symptom-
atic heart failure (Fig. 1). In addition, subclinical LV
dysfunction and symptomatic heart failure were present
in 85/175 (48%) and 19/175 (11%) of the patients with mild
COPD, respectively. Finally, of the patients with moderate
to severe COPD, 86/192 (45%) had subclinical LV
dysfunction and 32/192 (17%) had symptomatic heart
failure.
Of the 171 patients with COPD and subclinical LV
dysfunction, LVEF 40 was present in 60 (36%) of theand left ventricular dysfunction in vascular surgery patients.
lar.
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COPDþ symptomatic heart failure had LVEF 40
(p< 0.01).
Baseline characteristics
Clinical parameters are listed in Table 1. Patients with
1) COPD, 2) LV dysfunction or 3) COPDþ LV dysfunction were
older, were likely to be men, had a higher prevalence of
ischemic heart disease, abdominal aortic disease and were
more likely to be treated with beta-blockers or diuretics
compared to patients with normal pulmonary and normal LV
function. Patients with COPD or COPDþ LV dysfunction were
also more often smokers and receiving corticosteroids and
bronchodilators compared to patients with LV dysfunction or
those with normal pulmonary and LV function. In addition,
LV dysfunction with or without COPD was associated with
increased risk of renal dysfunction, hypertension and use of
oral anticoagulants and ACE inhibitors.
Association between COPD and LV dysfunction
Patients with COPD were less likely to have normal LV
function, with an odds ratio (OR) of 0.7 (95%-CI 0.5e0.9) for
mild COPD and 0.6 (95%-CI 0.4e0.8) for moderate/severe
COPD compared to patients with normal pulmonary func-
tion. Mild and moderate/severe COPD were both associated
with subclinical LV dysfunction (mild: OR 1.6; 95%-CI
1.1e2.3, moderate/severe: OR 1.7; 95%-CI 1.2e2.4). Mild
COPD was not significantly associated with heart failure (ORTable 1 Baseline characteristics.
Baseline characteristics No COPD and
normal LV function
[NZ 354]
COPD
[NZ
Demographics
Age (standard deviation) 64 (11) 68
Male (%) 245 (69) 118
Medical history (%)
Ischemic heart disease 104 (29) 61
Cerebrovascular disease 134 (38) 35
Abdominal aortic disease 112 (32) 71
Renal dysfunction 44 (12) 18
Diabetes mellitus 109 (31) 32
Hypertension 207 (59) 87
Hypercholesterolemia 219 (67) 84
Smoker, current 145 (41) 80
Medication (%)
Beta-blockers 246 (70) 122
Statins 253 (72) 99
Aspirin 222 (63) 81
Oral anticoagulants 45 (13) 16
ACE inhibitors 90 (25) 39
Angiotensin receptor blockers 42 (12) 25
Diuretics 62 (18) 33
Corticosteroids 17 (5) 39
Bronchodilators 14 (4) 44
COPDZ chronic obstructive pulmonary disease, LVZ left ventricular,1.2; 95%-CI 0.6e2.4). However, moderate/severe COPD was
associated with heart failure with an OR of 2.0 (95%-CI
1.2e3.6). These results are demonstrated in Fig. 2.
Association between COPD, LV dysfunction and
long-term follow-up
During follow-up, 164 (16%) patients died of whom 77 (47%)
had COPD. Mortality rate in patients with normal pulmo-
naryþ normal LV function was 8%; in those with COPD was
15%; in those with LV dysfunction was 20% and in patients
with both COPDþ LV dysfunction was 25% (p< 0.01).
Cumulative 6-year survival rates according to pulmonary
and LV function (log rank p< 0.01) are shown in Fig. 3. Of
the COPD patients who died during follow-up, 26 (34%) had
mild COPD and 51 (66%) had moderate/severe COPD.
A cardiovascular cause of death could be attributed in 54/77
(70%), 19/26 (73%) and 34/51 (67%) patients with no-, mild-
or moderate to severe COPD, respectively (pZ 0.351).
Mild COPD
Patients with mild COPDþ normal LV function did not have
an increased risk for all-cause mortality (HR 1.0; 95%-CI
0.4e2.1), compared to patients with normal pulmonary and
LV function. However, patients with mild COPDþ subclin-
ical LV dysfunction had an increased risk for all-cause
mortality with an HR of 1.7 (95%-CI 1.1e3.6). Patients with
mild COPDþ overt heart failure had the highest risk for all-
cause mortality with an HR of 2.7 (95% 1.2e5.9). These
results are shown in Table 2.145]
LV dysfunction
[NZ 284]
COPDþ LV
dysfunction
[NZ 222]
p-value
(8) 69 (10) 71 (9) <0.01
(81) 214 (75) 192 (87) <0.01
(42) 141 (50) 124 (56) <0.01
(24) 122 (43) 62 (28) <0.01
(49) 116 (41) 134 (60) <0.01
(12) 61 (22) 56 (25) <0.01
(22) 89 (31) 67 (30) 0.190
(60) 209 (74) 155 (70) <0.01
(60) 182 (67) 124 (57) 0.056
(55) 99 (35) 96 (43) 0.001
(84) 220 (78) 190 (86) <0.01
(68) 209 (74) 157 (71) 0.703
(56) 160 (56) 125 (56) 0.263
(10) 64 (23) 39 (18) 0.002
(27) 108 (38) 73 (33) 0.004
(17) 51 (18) 29 (13) 0.201
(23) 91 (32) 68 (31) <0.01
(27) 21 (7) 47 (21) <0.01
(30) 17 (6) 69 (31) <0.01
ACE inhibitorsZ angiotensine-converting enzyme inhibitors.
Figure 2 Association between chronic obstructive pulmonary
disease and left ventricular function. COPDZ chronic
obstructive pulmonary disease, LVZ left ventricular.
Figure 3 Cumulative 6-year survival. COPDZ chronic
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Patients with moderate/severe COPD had an increased risk
for all-cause mortality, compared to patients with normal
pulmonary function (HR 2.2; 95%-CI 1.3e4.5). HR was 2.5
(95%-CI 1.5e4.7) for patients with moderate/severe COPD
and subclinical LV dysfunction and 3.8 (95%-CI 1.6e9.1) for
patients with overt heart failure. These results are shown in
Table 2.
COPD and revised cardiac risk index
Multivariate analyses demonstrated that mild COPD was not
associated with an increased risk for long-term all-cause
mortality (HR 1.0; 95%-CI 0.6e1.6) in addition to RCR Index
risk factors. However, moderate/severe COPD was associ-
ated with an increased risk for long-term all-cause
mortality (HR 1.7; 95%-CI 1.2e2.5) in addition to the RCR
Index risk factors.
Discussion
The current study showed that both mild and moderate/
severe COPD are associated with increased risk of LV
dysfunction in vascular surgery patients. Approximately 1
out of 3 patients had COPD and in more than half of these
patients, LV dysfunction was also present. In COPD patients
with LV dysfunction, 3 out of 4 patients had subclinical LV
dysfunction. Both mild and moderate/severe COPD
patients, who had subclinical LV dysfunction, were at
increased risk for all-cause mortality compared to COPD
patients with normal LV function.
Several studies have been performed to evaluate the co-
existence between moderate/severe COPD and heart
failure. In 2005, Rutten et al. evaluated the prevalence of
heart failure in COPD patients aged above 65 years during
periods of clinical stability. They reported that heart failure
was present in 20.5% of these moderate/severe COPD
patients3 and concluded that the prevalence of heart
failure in stable COPD patients may be four times higher
than in the general population of individuals over 65 years
of age.3,13 In another observational study, Macchia et al.
showed that 1 out of 4 patients with heart failure among
a cohort of 1020 heart failure patients were also on treat-
ment for COPD. In addition, the presence of COPD reduced
the survival of these heart failure patients.4 The prevalenceobstructive pulmonary disease, LVZ left ventricular.
Table 2 Association between chronic obstructive pulmonary disease, left ventricular function and long-term all-cause
mortality.
Characteristics N (%) Univariable Multivariable
Hazard ratio [95%-CI] Hazard ratio [95%-CI]
No COPD normal LV function [NZ 354] 29 (8) reference e reference e
Mild COPD normal LV function [NZ 71] 7 (10) 1.2 0.5e2.6 1.0 0.4e2.1
subclinical LV dysfunction [NZ 85] 13 (15) 2.1 1.2e4.1 1.7 1.1e3.6
heart failure [NZ 19] 6 (32) 4.5 2.2e9.4 2.7 1.2e5.9
Moderate/severe COPD normal LV function [NZ 74] 15 (20) 3.0 1.7e5.4 2.2 1.3e4.5
subclinical LV dysfunction [NZ 86] 23 (27) 3.3 1.8e6.0 2.5 1.5e4.7
heart failure [NZ 32] 13 (41) 6.1 2.8e13.4 3.8 1.6e9.1
Multivariable analysis adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus,
hypertension, hypercholesterolemia and smoking status. COPDZ chronic obstructive pulmonary disease, LVZ left ventricular.
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because both disorders share similar risk factors such as
age, male gender and smoking14 or because of systemic
inflammation and oxidative stress associated with chronic
lung disease.
While preoperative cardiac risk indices such as the
widely used RCR Index, are used for more than 3 dec-
ades,12,15e17 the development and implementation of
preoperative pulmonary risk indices has been complicated
by conflicting results from multiple studies addressing this
issue.18e20 However, as stated in a systematic review of
‘preoperative pulmonary risk stratification for non-cardio-
thoracic surgery’ performed by Smetana et al., post-
operative pulmonary complications are equally prevalent
and contribute similarly to 1) morbidity, 2) mortality and 3)
length of hospital stay of surgical patients, in comparison
with cardiac complications.21 Among 15 studies reported in
this review article, 13 studies demonstrated that COPD was
the most frequently identified risk factor for postoperative
pulmonary complications.21 In preoperative risk stratifica-
tion of patients undergoing abdominal aortic aneurysm
repair, both COPD and heart failure have been adapted as
strong risk factors for adverse postoperative events.22e24
One could therefore ask the question whether it is advis-
able to use separated cardiac and pulmonary risk indices.
Especially, since it is known that COPD and heart failure
often co-exist and, as we have shown in the current study
that 1) mild COPD and subclinical LV dysfunction often co-
exist as well, 2) the combination of these two is associated
with an increased risk for long-term all-cause mortality and
3) moderate/severe COPD is an independently associated
with increased risk for long-term all-cause mortality, in
addition to the RCR Index. An important question remains if
diagnosing and treatment of pulmonary and LV dysfunction
will lead to improved long-term outcome. To address this
issue, a randomized controlled trial of vascular surgery
patients undergoing standard preoperative spirometry and
echocardiography, could provide us with final answers
addressing preoperative risk using an ‘integrated cardio-
pulmonary risk index’.
Potential limitations of these data merit consideration.
First, the study population consisted of patients referred to
a tertiary referral center and may not fully represent
a general population scheduled for elective vascular
surgery. Second, although two experienced investigatorsperformed off-line assessments of the obtained ultrasound
images, we cannot rule out inter-observer variability to
have had minor influence on our results. Third, not all
patients did have a preoperative pulmonary function test.
In those patients who did not have a pulmonary function
test, the diagnosis of COPD was based on symptoms and use
of pulmonary medication.
The current study demonstrated that both mild and
moderate/severe COPD were associated with an increased
risk for subclinical LV dysfunction in patients undergoing
vascular surgery. Patients with mild and moderate/severe
COPD who had subclinical LV dysfunction were at increased
risk for all-cause mortality, compared to COPD patients
with normal LV function. These data suggest that preop-
erative echocardiography may be useful to detect subclin-
ical cardiovascular disease and risk-stratify COPD patients
undergoing vascular surgery.
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